Amgen makes changes to board


They will come into effect on 1 January 2013

Amgen has made a number of changes to its board of directors.

Robert Bradway, chief executive officer, has been appointed as chairman of the board, with Vance Coffman, an Amgen director since 2007, as leading independent director. Both changes are effective from 1 January 2013.

In addition, Robert Eckert, former CEO at Mattel, will serve on Amgen’s Audit and Corporate Responsibility and Compliance Committees.

Sign up for your free email newsletter

Following this appointment and the previously announced retirement of Kevin Sharer from the board at the end of this year, from the start of next year the board will comprise 14 directors, 13 of whom are independent.